Literature DB >> 15328153

Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15.

Maria Wysocka1, Bernice M Benoit, Sarah Newton, Livio Azzoni, Luis J Montaner, Alain H Rook.   

Abstract

Patients with advanced cutaneous T-cell lymphoma (CTCL) exhibit profound defects in cell-mediated immunity. Host immune functions appear to play an integral role in mediating disease-controlling responses in CTCL, therefore we investigated the effects of synthetic oligode-oxynucleotides with CpG motifs (CpG ODN), which have been recognized as immune stimulatory by virtue of activation of dendritic cells (DCs) following binding to Toll-like receptor (TLR) 9. Peripheral blood mononuclear cells (PBMCs) from patients with advanced CTCL (erythroderma with circulating malignant T cells) and healthy volunteers were cultured with either CpG-A or CpG-B ODN. Patients' PBMCs exhibited marked induction of interferon-alpha (IFN-alpha) release following culture with CpG-A. Similarly significant activation of NK cells and CD8 T cells occurred as assessed by up-modulation of CD69 expression and by natural killer lytic activity. Nevertheless, the PBMCs of patients exhibited blunted responses to CpG-A compared to healthy volunteers. In such cases, IL-15 was capable of producing levels of NK activation that were superior to CpG-A, while the combined effects of CpG-A plus IL-15 induced maximal activation of NK cells and further enhanced activation of CD8 T cells. These findings have important implications for the potential enhancement of antitumor immunity among patients with advanced CTCL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15328153     DOI: 10.1182/blood-2004-03-1190

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

Review 1.  Important aspects of Toll-like receptors, ligands and their signaling pathways.

Authors:  Z L Chang
Journal:  Inflamm Res       Date:  2010-07-01       Impact factor: 4.575

2.  Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.

Authors:  Thomas A Stoklasek; Kimberly S Schluns; Leo Lefrançois
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

3.  Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation.

Authors:  Thorbjørn Krejsgaard; Andreas Willerslev-Olsen; Lise M Lindahl; Charlotte M Bonefeld; Sergei B Koralov; Carsten Geisler; Mariusz A Wasik; Robert Gniadecki; Mogens Kilian; Lars Iversen; Anders Woetmann; Niels Odum
Journal:  Blood       Date:  2014-06-23       Impact factor: 22.113

4.  Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma.

Authors:  Bethany Mundy-Bosse; Nathan Denlinger; Eric McLaughlin; Nitin Chakravarti; Susan Hwang; Li Chen; Hsiaoyin Charlene Mao; David Kline; Youssef Youssef; Rebecca Kohnken; Dean Anthony Lee; Gerard Lozanski; Aharon G Freud; Pierluigi Porcu; Basem William; Michael A Caligiuri; Anjali Mishra
Journal:  Blood Adv       Date:  2018-08-14

5.  Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma.

Authors:  Maria Wysocka; Noor Dawany; Bernice Benoit; Andrew V Kossenkov; Andrea B Troxel; Joel M Gelfand; Michael Kelly Sell; Louise C Showe; Alain H Rook
Journal:  Leuk Lymphoma       Date:  2011-10

Review 6.  Cutaneous T-cell lymphoma: Biologic targets for therapy.

Authors:  Jaehyuk Choi; Francine Foss
Journal:  Curr Hematol Malig Rep       Date:  2007-10       Impact factor: 3.952

7.  Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma.

Authors:  Elisabetta Capriotti; Eric C Vonderheid; Christopher J Thoburn; Mariusz A Wasik; David W Bahler; Allan D Hess
Journal:  Leuk Lymphoma       Date:  2008-06

8.  Safety and immunologic effects of IL-15 administration in nonhuman primates.

Authors:  Carolina Berger; Michael Berger; Robert C Hackman; Michael Gough; Carole Elliott; Michael C Jensen; Stanley R Riddell
Journal:  Blood       Date:  2009-07-15       Impact factor: 22.113

9.  Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas.

Authors:  Mirjana Urosevic; Kazuyasu Fujii; Bastien Calmels; Elisabeth Laine; Nikita Kobert; Bruce Acres; Reinhard Dummer
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

10.  Novel human interleukin-15 agonists.

Authors:  Xiaoyun Zhu; Warren D Marcus; Wenxin Xu; Hyung-il Lee; Kaiping Han; Jack O Egan; Jason L Yovandich; Peter R Rhode; Hing C Wong
Journal:  J Immunol       Date:  2009-08-26       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.